Pregnancy and contraceptive use among women participating in the FEM-PrEP trial
Data from the FEM-PrEP trial was analyzed to evaluate contraceptive use, pregnancy incidence, and study drug adherence by contraceptive method. The results found that women using combined oral contraceptives, particularly new users, were more likely to become pregnant and less likely to adhere to study product than injectable users.
Resource Details
- Study Type
- Observational study
- Year
- 2015
- Population
- HIV-uninfected women
- Author
- Callahan R, Nanda K, Kapiga S, Malahleha M, Mandala J, Ogada T, Van Damme L, Taylor D
More Publications & Resources
Standard Operating Procedure for Injectable Lenacapavir as Pre-exposure Prophylaxis
Provider Training Toolkit on Use of Oral and Long Acting HIV PrEP
Site/Facility Readiness Assessment Tool to Support Lenacapavir for HIV Prevention Introduction
Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of PrEP for Pregnant and Breastfeeding People
Tools for Active Safety Surveillance of Maternal and Infant Health Outcomes for Pregnant and Breastfeeding Users of Oral PrEP and PrEP Ring
Long-Acting Injectable Antiretroviral Drugs for Pregnant and Breastfeeding Women: Current Advances, Challenges, and Future Directions
Assessment of Facility Readiness for PrEP Provision in Antenatal and Postnatal Care Services
Oral PrEP for PBFP Training Package
Key Considerations for Integration of PrEP for Pregnant and Breastfeeding People into National Prevention of Vertical Transmission Polices
No results found.